Peptide Impurities Explained: Deletion, Truncation, Oxidation, and Deamidation

When a certificate of analysis reports a peptide as "98.6% pure by HPLC," the missing 1.4% is not anonymous dirt. It is a set of specific, characterizable molecules — each a small variant of the target sequence, each with its own structure, mass, and reason for existing. These are the related impurities, and they fall into two broad families by origin: the ones built during synthesis and the ones that form afterward, during storage. Understanding what they are turns a purity number from a grade into a story you can read: it tells you how well the peptide was made, how well it has been handled, and what the small extra peaks on a chromatogram actually represent. This guide walks through the main impurity types, how each forms, and how HPLC and mass spectrometry tell them apart.

Two origins: synthesis and storage

Every related impurity is either a process impurity, generated when the peptide was assembled, or a degradation impurity, generated after assembly as the molecule reacts with its environment. The distinction matters because the two behave differently over time. Process impurities are fixed at manufacture: their level is set the moment the batch is purified and does not change on the shelf. Degradation impurities are dynamic: they start low and accumulate with time, temperature, moisture, light, and pH. A purity figure on a certificate captures both at the instant of testing — which is exactly why a COA describes the sample as tested, not the vial as it will be six months later. Regulatory guidance on synthetic peptide drugs sorts related substances along these lines, and recommends orthogonal analytical methods to profile them.

Synthesis-derived impurities: truncations and deletions

Most research peptides are built by solid-phase peptide synthesis (SPPS), adding one amino acid at a time to a growing chain anchored to a resin. Each coupling step is efficient but never perfect, and the small fraction of chains that fail to react at a given step give rise to the two classic process impurities.

• Deletion sequences are missing one or more internal residues. They arise when a coupling step is incomplete: some chains do not receive that cycle's amino acid, yet still go on to couple the next one, producing a full-looking chain that is short by a residue in the middle. Because a deletion sequence differs from the target by exactly one (or a few) amino acids, it is often very close to the target in both mass and chromatographic behavior — which makes it one of the harder impurities to resolve.
• Truncation sequences are missing residues from a terminus — chains whose assembly stopped early. They are typically shorter than deletion sequences and, being more different from the target, are usually easier to separate.

Manufacturers actively manage these. A standard tactic is capping: after each coupling, any chains that failed to react have their exposed amino group chemically blocked, so they cannot participate in later cycles. Capping converts would-be deletion sequences into truncation sequences — shorter, more distinct species that purification can remove more cleanly. Related affinity-tag strategies label the full-length product so it can be pulled away from the truncated failures. Beyond these, SPPS can also introduce side-reaction products such as incomplete removal of protecting groups or sequence-specific side reactions, all of which add peaks to the profile.

Storage-derived impurities: oxidation, deamidation, hydrolysis

Even a flawlessly synthesized, highly pure peptide is chemically reactive, and certain residues degrade along well-characterized chemical routes once the material is exposed to oxygen, water, heat, or the wrong pH. These are the degradation pathways that erode purity on the shelf.

Oxidation (+16 Da)

Sulfur- and ring-containing residues — methionine, cysteine, and tryptophan — are the usual oxidation targets. Methionine is the textbook case: it oxidizes first to methionine sulfoxide, a partially reversible change, and on further oxidation to methionine sulfone, which is irreversible. Each added oxygen atom raises the molecular mass by about 16 Da, the diagnostic signature the mass spectrometer sees. Trace metal ions such as iron and copper catalyze the process by generating reactive oxygen species, which is one reason metal contamination and oxidative conditions are controlled during handling. Oxidation is a leading instability route for peptide and protein pharmaceuticals generally.

Deamidation (+1 Da)

Asparagine (Asn) and, more slowly, glutamine (Gln) lose their side-chain amide group and convert to aspartate/isoaspartate or glutamate, releasing ammonia. Mechanistically, asparagine deamidation proceeds through a five-membered succinimide intermediate formed by an intramolecular attack, which then hydrolyzes to a mixture of aspartyl and isoaspartyl products. The rate is strongly sequence-dependent: the residue immediately following the asparagine matters most, with small flexible residues like glycine accelerating it and bulky neighbors slowing it. It is also pH-dependent — the succinimide route accelerates sharply above about pH 8, while below roughly pH 4 acid-catalyzed hydrolysis dominates, leaving a relatively stable window around pH 3–5. Deamidation adds only about 1 Da, a small mass change that demands high-resolution mass spectrometry to detect confidently.

Hydrolysis and aggregation

The peptide backbone itself can cleave, and it is especially labile at aspartate–proline (Asp-Pro) bonds under acidic conditions, producing fragment species. Separately, peptides can associate into aggregates driven by hydrophobic and electrostatic interactions; while aggregation is a physical rather than covalent change, it is part of the same stability picture and can complicate both handling and analysis. The practical controls for all of these — keep the material cold, dry, dark, and lyophilized until use — are covered in peptide storage and stability.

How impurities are detected and identified

Profiling impurities takes two complementary measurements, because neither alone is sufficient. HPLC does the separating and the counting: reversed-phase chromatography spreads the target and its variants into distinct peaks, and area normalization at a backbone-absorbing wavelength assigns each a percentage — this is the purity number. But a chromatogram shows that a peak is present, not what it is. Mass spectrometry supplies the identity by weighing each species: an impurity that is +16 Da heavier than the target flags an oxidation; +1 Da flags a deamidation; a mass shorter by one residue's worth points to a deletion or truncation. Regulators and quality labs therefore recommend an orthogonal approach — standard HPLC/UHPLC paired with high-resolution LC-MS — precisely because some impurities that co-elute or nearly co-elute on one method are resolved by mass on the other. The small-mass changes make this pairing essential: a +1 Da deamidation product can hide under the main peak on a UV trace and only separate under high-resolution MS. For the deeper contrast between what each instrument proves, see HPLC purity vs mass spectrometry.

Why this matters when you read a COA

Knowing the impurity landscape changes how you interpret a certificate. A high purity number is good, but the shape of the impurity profile is informative too: a cluster of small early peaks reads differently from a single close-eluting shoulder near the main peak, which often signals a deletion sequence or a deamidation product that is chemically very similar to the target. It also reframes what purity does and does not tell you. Purity is a ratio among the peptide species that a UV detector sees; it is not the same as how much of the powder is peptide by mass, a separate quantity governed by counter-ions and water and explained in net peptide content vs. purity. And because degradation impurities accumulate after testing, a certificate is a snapshot: the batch that measured 99% at release can drift downward if it is stored warm, moist, or in solution. The practical reading skills — matching lot numbers, checking that the data includes the actual chromatogram and mass spectrum, and treating storage as part of quality — are laid out in how to read a peptide certificate of analysis.

FAQ

What is the difference between a deletion and a truncation sequence? A deletion sequence is missing one or more internal amino acids, usually from an incomplete coupling step during synthesis; a truncation sequence is missing residues from a terminus, from a chain whose assembly stopped early. Deletions tend to be closer to the target in mass and harder to separate; truncations are more distinct and easier to remove.

What does a +16 Da or +1 Da shift on a mass spectrum mean? A +16 Da shift indicates the addition of one oxygen atom — an oxidation, classically of methionine to its sulfoxide. A +1 Da shift indicates deamidation of asparagine or glutamine, where an amide converts to a carboxylic acid. The small +1 Da change typically requires high-resolution mass spectrometry to detect.

Which residues are most prone to degradation? Methionine, cysteine, and tryptophan are the main oxidation targets; asparagine and glutamine are the residues that deamidate; and aspartate–proline bonds are especially prone to acid-catalyzed backbone hydrolysis.

Do impurities increase over time? Process (synthesis) impurities are fixed at manufacture and do not change. Degradation impurities — oxidation, deamidation, hydrolysis — accumulate with time, heat, moisture, light, and unfavorable pH, which is why storage conditions directly affect the purity you actually have when you use the material.

Why use both HPLC and mass spectrometry to profile impurities? HPLC separates and quantifies peaks but cannot identify them; mass spectrometry identifies species by mass but is paired with separation for accurate quantitation. Because some impurities co-elute on one method yet resolve on the other, an orthogonal HPLC-plus-high-resolution-MS approach gives the most complete profile.

References

1. Daicel Pharma — Peptide Synthesis: Importance of Impurity Profiling in Therapeutic Peptides (impurity classes; orthogonal profiling).
2. Wunderlich et al., Journal of Peptide Science (2023) — Selective removal of truncation impurities after SPPS via orthogonal capping.
3. Sigma-Aldrich (Merck) — Peptide Stability and Potential Degradation Pathways (oxidation, deamidation, hydrolysis, aggregation).
4. Separation and Quantitation of Peptides with Methionine Oxidation and Asparagine Deamidation by HILIC-MS. J. Am. Soc. Mass Spectrom. (2017).
5. Liquid Chromatography–High Resolution Mass Spectrometry for Peptide Drug Quality Control. PMC (PMC4406950).
6. Bachem — Quality Control of Amino Acids & Peptides: A Guide (HPLC purity by area normalization).